For optimal antibody effectiveness, sometimes less is more

Christoph Wuelfing; Simon Dovedi

doi:10.1038/d41586-023-00244-5

For optimal antibody effectiveness, sometimes less is more

Christoph Wuelfing^*, Simon Dovedi

^*Corresponding author for this work

Research output: Contribution to journal › Review article (Academic Journal)

3 Citations (Scopus)

Abstract

Antibodies that activate stimulatory or inhibitory receptors are of great therapeutic interest for the treatment of cancer or autoimmune diseases. It emerges that such antibodies work better if they don’t bind to receptors too tightly.

Original language	English
Pages (from-to)	416-418
Number of pages	3
Journal	Nature
Volume	614
Issue number	7948
DOIs	https://doi.org/10.1038/d41586-023-00244-5
Publication status	Published - 1 Feb 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/d41586-023-00244-5

Handle.net

Persistent link

Cite this

@article{f0b66b3a6a2743de8c688bd7213ec986,

title = "For optimal antibody effectiveness, sometimes less is more",

abstract = "Antibodies that activate stimulatory or inhibitory receptors are of great therapeutic interest for the treatment of cancer or autoimmune diseases. It emerges that such antibodies work better if they don{\textquoteright}t bind to receptors too tightly.",

author = "Christoph Wuelfing and Simon Dovedi",

year = "2023",

month = feb,

day = "1",

doi = "10.1038/d41586-023-00244-5",

language = "English",

volume = "614",

pages = "416--418",

journal = "Nature",

issn = "0028-0836",

publisher = "Springer Nature",

number = "7948",

}

TY - JOUR

T1 - For optimal antibody effectiveness, sometimes less is more

AU - Wuelfing, Christoph

AU - Dovedi, Simon

PY - 2023/2/1

Y1 - 2023/2/1

N2 - Antibodies that activate stimulatory or inhibitory receptors are of great therapeutic interest for the treatment of cancer or autoimmune diseases. It emerges that such antibodies work better if they don’t bind to receptors too tightly.

AB - Antibodies that activate stimulatory or inhibitory receptors are of great therapeutic interest for the treatment of cancer or autoimmune diseases. It emerges that such antibodies work better if they don’t bind to receptors too tightly.

U2 - 10.1038/d41586-023-00244-5

DO - 10.1038/d41586-023-00244-5

M3 - Review article (Academic Journal)

C2 - 36725942

SN - 0028-0836

VL - 614

SP - 416

EP - 418

JO - Nature

JF - Nature

IS - 7948

ER -

For optimal antibody effectiveness, sometimes less is more

Abstract

UN SDGs

Access to Document

Handle.net

Fingerprint

Cite this